{
    "0": {
        "pmid": [
            "15870317",
            "20863418",
            "17991656",
            "15585783",
            "20032496",
            "24233255",
            "11964956",
            "7503180",
            "3113290",
            "11978748",
            "15699689",
            "4274545",
            "16978805",
            "17460489",
            "15343178",
            "20639792",
            "16801182",
            "12604972",
            "17433577",
            "19561548",
            "17325558",
            "19879595"
        ],
        "query": "What are the latest scholarly papers on the use of probiotics and prebiotics for reducing the incidence of necrotizing enterocolitis in very low birth weight preterm neonates? I am particularly interested in systematic reviews and meta-analyses that provide evidence on the effectiveness of probiotics in modulating the composition of the intestinal microflora, suppressing harmful microorganism colonization, stimulating bifidobacterial growth, reducing stool viscosity, improving gastrointestinal transit time, and enhancing feed tolerance."
    },
    "1": {
        "pmid": [
            "7872224",
            "15614200",
            "8247594",
            "17161227",
            "15955465",
            "1324483",
            "16391591",
            "12569112",
            "6096282",
            "18041436",
            "1313163"
        ],
        "query": "\"What are the findings of meta-analyses on the impact of glucomannan on plasma lipids, body weight, fasting blood glucose, and blood pressure in clinical trials? Do these studies show consistent results or conflicting outcomes? How does glucomannan affect total cholesterol, LDL cholesterol, triglycerides, body weight, and fasting blood glucose? Are there any specific patient groups, such as pediatric patients, patients receiving dietary modification, or patients with impaired glucose metabolism, that do not benefit from glucomannan to the same degree? Are there any studies indicating the impact of glucomannan on HDL cholesterol or blood pressure? I am particularly interested in scholarly papers reporting on randomized controlled trials of glucomannan with detailed sample sizes and critical insights.\""
    },
    "2": {
        "pmid": [
            "11685356",
            "17261567",
            "22928432",
            "26578718",
            "29741911",
            "19633231",
            "27209621",
            "19956928",
            "28477270",
            "29776815",
            "25514139",
            "17293471",
            "21059327",
            "15466722",
            "23632778",
            "28273424",
            "21663722",
            "12860546",
            "24630956",
            "22886496",
            "19684298"
        ],
        "query": "What is the role of quadriceps tendon (QT) autograft in primary ACL reconstruction? Can a Bayesian network meta-analysis compare the outcomes of primary ACL reconstruction with QT autograft to those with patellar tendon (PT) and hamstring tendon (HT) autografts? What are the rates of Lachman test, Pivot shift test, and instrumental laxity greater than 3 mm with QT autograft? Does QT autograft have a lower rate of autograft failure compared to other autograft options? Does QT autograft result in a reduced rate of anterior knee pain (AKP) compared to PT autograft? Is quadriceps tendon autograft a feasible option for primary ACL reconstruction?"
    },
    "3": {
        "pmid": [
            "16687205",
            "20597708",
            "22982689",
            "15643227",
            "16452102",
            "19093918",
            "15469455",
            "16730620",
            "23239364",
            "21275438",
            "19021151",
            "19747069",
            "21539525",
            "12590356",
            "22091573"
        ],
        "query": "What is the impact of drugs with anti-cholinergic properties on relevant health outcomes, particularly in terms of cognitive and physical function, delirium, and mortality? I am looking for scholarly papers that provide detailed insights and critical analysis of the effects of medications with anti-cholinergic properties on these specific health outcomes."
    },
    "4": {
        "pmid": [
            "15616893",
            "14749454",
            "8473517",
            "9925126",
            "15447922",
            "14623654",
            "12064330",
            "8950879",
            "15465502",
            "14506950",
            "12110423",
            "11180916",
            "16481635",
            "10443663",
            "10227010",
            "11346808",
            "10750566",
            "15885294",
            "9737352",
            "11793169"
        ],
        "query": "I am looking for scholarly papers that discuss the association between low intake of vitamin K and an increased risk of fracture. Specifically, I am interested in assessing whether oral supplementation of vitamin K, including phytonadione and menaquinone, can reduce bone loss and prevent fractures. I would like to find a systematic review that examines the effects of supplementation with phytonadione and menaquinone-4 on bone loss and incident fractures, particularly among Japanese patients."
    },
    "5": {
        "pmid": [
            "7058834",
            "2149210",
            "9253097",
            "9628709",
            "2727468",
            "24469864",
            "10086815",
            "8464977",
            "8345115",
            "8444625",
            "9233870",
            "2521930",
            "2145877",
            "8484150",
            "2727469",
            "3826269",
            "1826175",
            "2141231"
        ],
        "query": "I am looking for a collection of scholarly papers that have conducted a systematic review of randomized controlled trials to assess the effectiveness of workplace interventions in preventing low back pain. Specifically, I am interested in the findings regarding the effectiveness of workplace exercise, braces, education, and workplace modification plus education in preventing low back pain."
    },
    "6": {
        "pmid": [
            "9039248",
            "11157015",
            "8162979",
            "9817289",
            "8606899",
            "10974183",
            "10489824",
            "11467624",
            "12003051",
            "7570431",
            "10335749",
            "11864800",
            "11864794",
            "3553497",
            "9886591",
            "11824949",
            "11501727",
            "9105068"
        ],
        "query": "What is the consistent magnitude of minimally important difference (MID) estimates for health-related quality of life instruments across different factors such as disease-specific or generic instruments, number of response options, and types of conditions (acute or chronic)? Are negative changes associated with larger effect sizes (ESs)? How do population-based estimation procedures and brief follow-up affect the ESs?"
    },
    "7": {
        "pmid": [
            "22198456",
            "4532214",
            "24061331",
            "9065681",
            "22907732",
            "20881846",
            "23972788",
            "11534926",
            "23676529",
            "8422222",
            "21681817",
            "24351233",
            "3503236",
            "441384",
            "21135327",
            "3404593",
            "11982447",
            "15724870",
            "12006901",
            "23671484",
            "22901350",
            "15930067",
            "21693549",
            "18090504",
            "21452176",
            "12006900",
            "14680716",
            "21105279",
            "22417933",
            "19958308",
            "23808960",
            "18090457",
            "24135509",
            "11434404",
            "23680817",
            "20473065"
        ],
        "query": "What are the latest systematic review findings on long-term pharmacological treatments for panic disorder, generalized anxiety disorder, and social anxiety disorder? Which medications, such as paroxetine, escitalopram, clonazepam, pregabalin, quetiapine, agomelatine, and vortioxetine, have been found effective for long-term treatment of these anxiety disorders? Is there any evidence on the optimal length and dosage of these medications to minimize the risk of relapse?"
    },
    "8": {
        "pmid": [
            "22828661",
            "23362293",
            "12749495",
            "2871989",
            "20207412",
            "16125826",
            "16723370",
            "24002488",
            "21852659",
            "22954655",
            "19081744",
            "22721899",
            "15694506",
            "22081739",
            "24550454",
            "24845800",
            "26388040",
            "23599908",
            "3504064",
            "19329003",
            "18162935",
            "17136746",
            "2860339",
            "5628631",
            "24385620"
        ],
        "query": "What is the impact of interventions on health outcomes in low-middle income countries? I am looking for published literature that discusses the spillover effects of these interventions, specifically focusing on reduced disease transmission, social proximity, and substitution of resources within households. I am interested in understanding the methods used to estimate these effects and the evidence of publication bias. Additionally, I would like to find information on the effectiveness of vaccines and mass drug administration in controlling infectious diseases and if there are any other interventions that have been proven to have spillover effects."
    },
    "9": {
        "pmid": [
            "9179834",
            "4527012",
            "15983311",
            "23816038",
            "2584171",
            "15684636",
            "3024339",
            "22818724",
            "2628685",
            "19862578",
            "2584178",
            "8842601",
            "1804280",
            "16186262",
            "12610033",
            "11213866",
            "19390093",
            "12401738",
            "12649049",
            "18613991",
            "8366922",
            "19581618",
            "17316098",
            "17973175",
            "10938048",
            "18779465",
            "11772893",
            "11059437",
            "18373577",
            "10957848",
            "19038472",
            "21242556"
        ],
        "query": "What are the findings of systematic reviews and meta-analyses on the impact of information technology-based interventions on changes in hemoglobin A1c levels in people with type 2 diabetes? How does the incorporation of chronic care model elements in these interventions affect the improvements in HbA1c levels? Are there any significant effects on low-density lipoprotein levels and blood pressure? Is there evidence of cost savings in the provision of care?"
    },
    "10": {
        "pmid": [
            "11498066",
            "9489599",
            "9694707",
            "14749150",
            "16672168",
            "15911731",
            "12755792",
            "9247460",
            "16453051"
        ],
        "query": "What are the latest scholarly papers on the efficacy of oral cobalamin treatment in elderly patients with cobalamin deficiency? I am particularly interested in the improvement in serum vitamin B12 levels and hematological parameters such as hemoglobin level, mean erythrocyte cell volume, and reticulocyte count. Additionally, I would like to know more about the advantages of oral cobalamin therapy compared to monthly injections, including the avoidance of discomfort, inconvenience, and cost."
    }
}